Important traits include of hydroxyapatite crystal size in cancellous bone material [1], macroscopic trait shape [1], trabecular microarchitecture [1], haversian canal presence in compact bone material [2], cross-sectional area [1,3], and overall bone density [3,4]
A 2025 JAMA Psychiatry clinical trial found that adults with alcohol use disorder taking weekly semaglutide experienced significant reductions in alcohol cravings and consumption compared to placebo (source)
Its loss reduces basal metabolic rate which is one reason GLP-1 discontinuation is associated with significant weight regain risk
As the authors reported: Our findings demonstrate that all three GLP-1 analogs exhibit significant anti-obesity effects in MC4R KO mice. Significant weight and metabolic improvements Weight reduction occurred across all treatment groups: Semaglutide reduced body weight by an average of 19.7 percent Retatrutide achieved a 24.1 percent reduction Tirzepatide , which targets both GLP-1 and GIP receptors, produced the largest effect with a 31.6 percent reduction Importantly, these outcomes occurred in animals completely lacking MC4R function
Additionally, dietary protein-derived metabolites, including tryptophan-indole, as well as LPS from Gram-negative bacteria, directly promote the production of GLP-1 (66, 67)
Retatrutide is a triple agonist that includes full GLP-1 activation as part of its mechanism, plus GIP and glucagon receptor activity
.png)
